UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ FORM 10-K _________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 ____________________________ ...

Teleflex Incorporated (NYSE:TFX) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Lawrence Keusch - Vice President, Investor Relations & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer Thomas Powell - Executive Vice President & Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Mike Sarcone - Jefferies Shagun Singh - RBC Mike Polark - Wolfe Research Jayson Bedford - Raymond James Lawrence Biegelsen - Wells F ...

| --- | --- | --- | |----------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Fourth Quarter 2022 Earnings Conference Call | | | Conference Call Logistics The call can be accessed by dialing 1 866 813 9403 (U.S.) or +44 204 525 0658 (all other locations). Today's Speakers Tfeleflex® Note on Forward-Looking Statements Note on Non-GAAP Financial Measures Executive Overview Liam Kelly - Chairman, President and CEO 5 Q4 Performance S ...

Financial Data and Key Metrics Changes - Teleflex reported revenues of $686.8 million for Q3 2022, a year-over-year decline of 1.9% on a reported basis and an increase of 2.4% on a constant currency basis [6] - Adjusted earnings per share decreased by 6.8% year-over-year to $3.27 [6][36] - Adjusted gross margin was 58.7%, an 80-basis point decrease compared to the prior year [33] - Adjusted operating margin was 26.9%, reflecting a 160-basis point decline year-over-year [34] Business Line Data and Key Metrics Changes - The OEM business unit achieved double-digit constant currency year-over-year revenue growth [7] - Interventional business unit grew approximately 9% [7] - Surgical business reported mid-single-digit constant currency growth year-over-year [7] - UroLift revenue declined 5.8% year-over-year, while the remainder of the high-growth portfolio showed healthy gains with 14% growth [8] Market Data and Key Metrics Changes - Americas revenues were $405.1 million, a 2.7% decline year-over-year [12] - EMEA revenues increased by 3.4% year-over-year to $128.4 million [13] - Asia revenues grew robustly by 20.5% year-over-year to $82 million, with China exceeding 19% growth [13] Company Strategy and Development Direction - The acquisition of Standard Bariatrics for $170 million aims to enhance Teleflex's surgical portfolio and is expected to be accretive to long-term revenue growth [22][24] - The company continues to focus on investing in high-growth portfolios while managing costs [48] - Teleflex is committed to expanding its UroLift product internationally, with ongoing training for new physicians and market development in Japan and China [29][31] Management's Comments on Operating Environment and Future Outlook - Management noted that patient visits to urologists were down high single digits year-over-year, impacting UroLift sales [19] - There is optimism regarding the recovery of patient flow and staffing levels, which are expected to improve in the future [55][68] - The company maintains its 2022 constant currency revenue growth guidance of 3.25% to 4.25% [39] Other Important Information - The company experienced elevated supply chain disruptions, particularly affecting Vascular and Interventional businesses [10] - The U.S. Department of Justice closed its investigation into NeoTract Inc., a subsidiary of Teleflex, in August 2022 [32] Q&A Session Summary Question: Trends in UroLift patient flow compared to pre-COVID - Management indicated that patient flow was down approximately 12% in Q2 and high single digits in Q3, with staffing shortages impacting the situation [53][55] Question: Outlook for Japan and international expansion - Management expressed confidence in the adoption of UroLift in Japan and noted that the market recovery is essential for future growth [56][58] Question: Impact of revenue slowdown on margin expansion - Management acknowledged that revenue slowdown affects margin leverage but emphasized ongoing restructuring programs and growth in high-margin portfolios [60][62] Question: UroLift sales dynamics and patient cancellations - Management confirmed that there is a lag in patient visits to procedures and noted that staffing shortages in urology offices remain a challenge [86] Question: Confidence in achieving future growth targets - Management remains confident in achieving a 6% to 7% CAGR, supported by the addition of Standard Bariatrics and the potential recovery in UroLift sales [68]

Teleflex, Inc. (NYSE:TFX) Q2 2022 Earnings Conference Call July 28, 2022 8:00 AM ET Company Participants Lawrence Keusch - VP, IR & Strategy Development Liam Kelly - Chairman, President & CEO Thomas Powell - EVP & CFO Conference Call Participants Cecilia Furlong - Morgan Stanley Jayson Bedford - Raymond James & Associates Shagun Chadha - RBC Capital Markets Michael Polark - Wolfe Research Richard Newitter - Truist Securities Michael Matson - Needham & Company Matthew Mishan - KeyBanc Capital Markets Craig B ...

| --- | --- | --- | |--------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Q1 2022 Earnings Conference Call | | | ിfeleflex® Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on April 28, 2022 either on the Teleflex website or by telephone. The call can be accessed by dia ...

Teleflex Incorporated (NYSE:TFX) Q1 2022 Earnings Conference Call April 28, 2022 8:00 AM ET Company Participants Lawrence Keusch - VP, Investor Relations and Strategy Development Liam Kelly - Chairman, President and Chief Executive Officer Thomas Powell - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James Cecilia Furlong - Morgan Stanley Shagun Singh - RBC Capital Markets Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Richard Newitter - T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ FORM 10-K _________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 1-5353 ____________________________ ...

Financial Data and Key Metrics Changes - In Q4 2021, Teleflex achieved 7.9% constant currency revenue growth year-over-year and 10.4% growth compared to Q4 2019, with an adjusted earnings per share increase of 10.8% year-over-year [10][14][43] - For the full year 2021, constant currency sales growth was 8.8%, adjusted operating margin expanded by 310 basis points, and adjusted earnings per share reached $13.33, a 24.9% increase year-over-year [14][43] Business Line Data and Key Metrics Changes - Americas revenue was $451.7 million in Q4, representing 7.6% year-over-year growth, driven by Surgical, Vascular, and Interventional segments [17] - EMEA revenues increased 4.8% year-over-year to $164.5 million, with Interventional, Surgical, and Vascular Access products leading the growth [17] - Asia revenues were $78.5 million, a 0.5% year-over-year increase, with a 6.7% rise when excluding the respiratory divestiture [18] - Vascular Access revenue grew 6.4% to $193 million, with notable growth in the PICC portfolio [19] - Interventional revenue was $114.9 million, up 8.2% year-over-year, with strong demand for complex catheters [20] - Anesthesia and Emergency Medicine revenue increased 20.5% to $102.8 million, driven by Hemostat products [22] - Surgical revenue was $106.4 million, representing 16.1% growth year-over-year [22] - Interventional Urology revenue decreased 1% year-over-year to $92.9 million, impacted by COVID-19 [23] - OEM revenues increased 3.9% year-over-year to $67.2 million [23] - Other category revenues declined 12.2% to $84.7 million due to the respiratory divestiture [24] Market Data and Key Metrics Changes - The Americas, EMEA, Asia, and OEM segments all demonstrated constant currency revenue growth over 2020, despite COVID-19 headwinds [16] - The company noted that COVID-19 significantly impacted elective surgical procedures, particularly in December [12][13] Company Strategy and Development Direction - Teleflex is focused on driving durable growth, expanding margins, and optimizing its portfolio through acquisitions and divestitures [14][40] - The company plans to enhance its UroLift product line and expand into international markets, with significant opportunities in Japan and Brazil [30][32] - The strategy includes maintaining financial discipline while pursuing M&A opportunities in the $60 million to $300 million revenue range [68][76] Management's Comments on Operating Environment and Future Outlook - Management expects the impact of COVID-19 to be lower in 2022 compared to 2021, with improvements in elective surgical procedures anticipated [37][38] - The company is prepared to adjust spending based on the level of COVID disruption while continuing to invest in growth drivers [39] - For 2022, constant currency revenue growth is expected to be between 4% and 5.5%, with UroLift projected to grow approximately 15% [48][49] Other Important Information - Adjusted gross margin for Q4 was 58.8%, an 80 basis point increase year-over-year, while adjusted operating margin was 27.6%, a 100 basis point increase [42] - Cash flow from operations for 2021 totaled $652.1 million, a significant increase from $437.1 million in 2020 [44] - The company has a solid balance sheet with a cash balance of $445.1 million and net leverage of approximately 1.7x [45] Q&A Session Summary Question: Current environment compared to a month ago - Management noted that parts of the business perform differently during COVID outbreaks, with expectations for improvement in February and March as hospitals reopen [64][66] Question: Portfolio optimization in the current environment - Management expressed confidence in their financial position and ability to pursue acquisitions, noting improved valuation expectations [68][69] Question: UroLift growth and reimbursement changes - UroLift is expected to grow 15% in 2022, with contributions primarily from the U.S. market, while international markets will ramp up in subsequent years [71][73] Question: M&A criteria and areas of interest - The company is looking for assets in the $60 million to $300 million revenue range that fit strategic pillars and have strong IP [76] Question: UroLift growth cadence and international contributions - UroLift growth is expected to be lower in the first half of 2022 due to COVID, with stronger growth anticipated in the second half [81] Question: Impact of inflation and FX on margins - Inflation in Q4 was higher than expected, and management anticipates continued inflationary pressures in 2022, impacting margins [88][90]

| --- | --- | --- | |--------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | Teleflex Incorporated Fourth Quarter 2021 Earnings Conference Call | | | ിfeleflex® Conference Call Logistics The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 24, 2022 either on the Teleflex website or by telephone. The ...